Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.60 |
| ▸ | PPARA | Q07869 | 7/20 | 0.60 |
| ▸ | MARS1 | P56192 | 4/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692571 | 0.86 | PPARG (0.57) | PPARGPPARAPPARDCNR1CNR2 | |
| SCHEMBL4692489 | 0.83 | MARS1 (0.60) | PPARGPPARAMARS1NR1H4PPARD | |
| SCHEMBL4692553 | 0.80 | MARS1 (0.62) | PPARGPPARAMARS1PPARD | |
| SCHEMBL4692592 | 0.79 | PPARG (0.58) | PPARGPPARAMARS1NR1H4PPARD | |
| SCHEMBL4688189 | 0.79 | NR1H4 (0.61) | PPARGPPARAMARS1NR1H4 | |
| SCHEMBL4694870 | 0.78 | PPARG (0.59) | PPARGPPARANR1H4PPARDCNR1 | |
| SCHEMBL2565390 | 0.76 | SMPD1 (0.55) | PPARGPPARACNR1SMPD1 | |
| SCHEMBL4692597 | 0.72 | FAAH (0.57) | PPARGPPARAMARS1PPARD | |
| SCHEMBL31459605 | 0.71 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL1739427 | 0.70 | MARS1 (0.60) | MARS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885MARS1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.